💊
Afqlir
aflibercept
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion
✅ Authorised
Biosimilar
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Afqlir is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV)
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/afqlir